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A number of studies have previously shown a lower prevalence of
non-BCG vaccinations among children with leukaemia than in
controls (Kneale et al, 1986; McKinney et al, 1987; Hartley et al,
1988; Nishi and Miyake, 1989; Kaatsch et al, 1996; Dockerty et al,
1999; Schuz et al, 1999).
Recently, the results of a large case-control study conducted in
the United States raised the possibility that conjugate vaccine
against  Haemophilus influenzae type b (Hib) could reduce the risk
of childhood leukemia (Groves et al, 1999). Vaccination history
was obtained from mothers or physicians of 439 case-control
pairs, with cases diagnosed with childhood acute lymphoblastic
leukaemia. An odds ratio of 0.55 (95% CI 0.35–0.87) was found
for vaccination against Hib during the era when conjugate vaccine
was predominant. No significant effect was detected for vaccine
against Hib during the era when polysaccharide vaccination was in
use, nor for any other vaccine. There was no a priori hypothesis,
nor biological mechanism related to the Hib conjugate vaccine. It
remains unclear if the finding was due to vaccination itself or
avoidance of infection – alternative explanations also include
chance, bias and confounding.
The aim of the present study was to evaluate the effect of
different timing and number of doses of a conjugate Hib vaccine.
A rare opportunity to compare different administration schemes
within the setting of an intervention trial was provided by a nation-
wide vaccination trial conducted in Finland in the 1980s (Eskola
et al, 1990). This approach minimizes the effects of bias and
confounding due to known and unknown risk factors.
MATERIAL AND METHODS
A nation-wide vaccine trial compared vaccination against
Haemophilus influenzae type b (Hib) with multiple doses of a
conjugate vaccine in infancy (early intervention) versus a single
dose at the age of two years (late intervention) (Eskola et al, 1990).
The vaccine consisted of heat-sized Hib capsular polysaccharide
coupled to diphtheria toxoid (PRP-D) (Schneerson et al, 1980). All
114 000 children born in Finland between October 1, 1985 and
August 31, 1987 were enrolled with participation rate of 98%. The
children were allocated to the trial arms based on the date of birth.
All children with an odd day of birth were assigned to the early
intervention arm with vaccination at the ages 3, 4, 6 and a fourth
dose given between 14 and 18 months, while children with an even
day of birth were assigned to the late intervention arm and were
not vaccinated until they reached the age of 24 months, when
they received one dose. All the children also received standard
vaccination regime including tuberculosis (BCG), diphtheria-
pertussis-tetanus (DPT), inactivated polio (IPV) and measles-
mumps-rubella (MMR) vaccine.
Information on the number of boys and girls born on odd and
even dates during the periods of interest were obtained from 
the Finnish Population Registry (Table 1). Also, the number of
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Table 1 Numbers of children, person-years (PYRs) and leukaemia cases
by period, odd versus even date and sex
Odd date Even date
Boys Girls Boys Girls
No. 32 689 31 227 31 390 29 845
PYRs 341 691 327 354 327 850 312 190
Cases 15 18 18 26Hib vaccination and childhood leukaemia 957
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children alive in each group by year and sex was acquired. The
length of follow-up (through 1996) was 9–11 years among chil-
dren in the trial (born 1985–1987).
All cases of childhood leukaemia diagnosed in Finland were iden-
tified from the Finnish Cancer Registry, which is a nation-wide,
population-based cancer registry (Teppo et al, 1994). Complete
coverage of the cancer registry was ensured by crosschecking the
case lists at all hospitals treating childhood leukaemia and from
mortality records. All childhood leukaemia cases were histologically
confirmed with bone marrow biopsy. In addition, incidence rates of
childhood leukaemia in Finland in 1977–1996 by five-year age group
were obtained from the Finnish Cancer Registry.
Poisson regression analysis of leukaemia incidence rates was
conducted using the number of cases as the outcome variable and
the natural logarithm of number of children at risk as an offset
term (Breslow and Day, 1987). For comparison of the early and
late vaccination groups, a binary variable based on odd or even
date of birth was used. In the analysis of temporal trends, a contin-
uous calendar year term was used.
RESULTS
The numbers of children born during the trial period and person-
years at risk are presented in Table 1.
A total of 77 leukaemia cases were diagnosed from birth
through age 11 among subjects born during the trial period
(1985–1987). Of them, 33 were observed among children born on
an odd date, i.e., belonging to the early vaccination arm, while 44
were diagnosed among children in the late intervention arm. This
corresponds to a relative risk of 0.72 (95% CI 0.46–1.13) for
subjects born on an odd date. The cumulative incidence of child-
hood leukaemia in the two groups is shown in Figure 1.
Sixty-seven of the cases were acute lymphoblastic leukaemias
(ALL). Among these cases 29 were born on odd days and 38 on
even days. The corresponding relative risk for the early vaccina-
tion arm was 0.73 (95% CI 0.45–1.18).
When the analysis was restricted to cases diagnosed between
the ages of three months and two years, i.e. the time period during
which only the subjects in the early-intervention arm had been
vaccinated, there were four leukaemia cases in the early vaccina-
tion arm and ten cases in the late vaccination arm. The corre-
sponding relative risk was 0.47 (95% CI 0.09–2.59). For ALL
alone, the numbers of cases in these groups were one and five (RR
0.19, 95% CI 0.00–1.72).
Incidence rate of childhood leukaemia remained practically
constant, around 5 per 100 000 person-years in Finland in
1977–1996 (Figure 2). Poisson regression analysis showed no
evidence for temporal trend (less than 1% change in relative risk
per year), both overall (RR 1.00 per year, 95% CI 0.99–1.01) and
for each five-year age groups (RR 1.01 per year, 95% CI
0.99–1.03 for 0–4 years of age, RR 1.00, 95% CI 0.98–1.02 for
5–9 years of age and RR 1.01, 0.98–1.03 for 10–14 years of age).
DISCUSSION
There was a suggestion of a lower risk of childhood leukaemia
among Finnish children who received multiple doses of
Haemophilus influenzae type b conjugate vaccine in the first year
of life than in those who received only a single dose at the age of
two years. As expected, the effect was most pronounced prior to
the age of two years, i.e. before the late intervention group was
vaccinated. The design of the trial with allocation of intervention
based on date of birth and prospective follow-up minimized the
potential for bias and confounding. Very high participation rate
reduced exposure misclassification to a minimum and complete
ascertainment of cases was achieved by using the data from the
Finnish Cancer Registry, based on clinical, pathological and cause
of death records. However, we were not able to verify if the vacci-
nation indeed took place for a given individual, even though it was
very likely given the participation rate of 98%. We find it unlikely
that selection bias could account for our results, because the
analyses were conducted on the basis of intention to treat, i.e.,
non-participants were included in the study population.
The majority of previous studies have shown a larger proportion
of unvaccinated children among leukaemia cases than controls
(Kneale et al, 1986; McKinney et al, 1987; Hartley et al, 1988;
Nishi and Miyake, 1989; Kaatsch et al, 1996; Schuz et al, 1999),
but these findings have not been observed in all studies (Innis,
1965; Stewart and Hewitt, 1965; Salonen, 1976). Previously, only
a German study has included the Hib vaccine among exposures
studied, but the effects of Hib (or any other specific vaccination)
were not reported separately (Kaatsch et al, 1996; Schuz et al,
1999). A US case-control study, however, found a statistically
significant protective effect of Hib vaccination for the period when
conjugate vaccine prevailed, but not for polysaccharide vaccine
era (Groves et al, 1999).
No plausible biological mechanism has yet been identified,
which could explain an apparent protective effect of early,
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Figure 1 Cumulative incidence of childhood leukaemia by age. Thick line:
even date of birth, with a single vaccination at 24 months of age. Thin line:
odd date of birth, with several immunizations between three and 18 months
of age
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Figure 2 Incidence rate of childhood leukaemia by age group in Finland in
1977–1996. Solid line: overall, 0–14 years, dotted line: 0–4 years, dashed
line: 5–9 years, thin line: 10–14 years958 A Auvinen et al
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repeated Hib vaccination against childhood acute lymphoblastic
leukaemia. It is possible that the vaccination stimulates the
immune system in some way that reduces the subsequent risk of
leukaemia, with the effect possibly depending on the age at first vacci-
nation or the number of vaccinations. An infective basis of childhood
leukaemia has been postulated and some limited evidence provided
for it (Greaves, 1997; Kinlen, 1998; Smith et al, 1997). In particular,
the delayed exposure hypothesis postulates that a small fraction of
children are predisposed to leukaemia due to a somatic mutation,
which occurs in utero. Early antigenic exposures are believed to
protect against the development of leukaemia, while delayed exposure
to the same antigens may actually trigger the preleukaemic clone to
expand and progress to a leukaemia (Greaves, 1999). In addition, the
incidence of childhood leukaemia has remained stable since the intro-
duction of large-scale Hib vaccinations, even as the incidence of clin-
ical and subclinical Hib infection has declined (Takala et al, 1991;
Peltola et al, 1992; Takala et al, 1994). Also, invasive Hib infections
are no more common than childhood ALL. Therefore, a protective
effect due to prevention of Hib infection per se seems unlikely.
However, vaccination decreases materially the prevalence of asymp-
tomatic carriers (Takala et al, 1991).
Incidence rates of childhood leukaemia in Finland are comparable
to other countries with nation-wide cancer registration (Parkin et al,
1998). No changes in incidence rates of childhood leukaemia 
have been observed in Finland following the introduction of a Hib
vaccine programme in 1990. However, the type of vaccine used in
the trial (PRP-D) was different from those used for the nation-wide
vaccination policy (PRP-T in 1990–1991 and HbOC since 1991).
The PRP-D and PRP-T vaccines are similar in that the polysaccha-
ride from the capsule of Hib is covalently bound to a bacterial toxoid
(a protein exotoxin denatured by heat treatment) from either
Clostridium tetani (PRP-T) or Corynebacterium diphtheriae (PRP-
D). In HbOC, the Hib oligosaccharide is coupled with the exotoxin
of Corynebacterium diphtheriae strain CRM197; the exotoxin from
this mutant strain does not require heat-treatment because it is
nontoxic to humans. In view of the aforementioned differences
between the PRP-D vaccine, which was used in the 1986–1987 trial,
and the HbOC vaccine, which is currently in use, it may be informa-
tive to assess the incidence of childhood leukemia in Finland among
subjects who participated in the nationwide clinical trial which
compared early vaccination with PRP-D versus HbOC during
1988–1989 (Peltola et al, 1994).
Based on the results of studies published so far, we find it plau-
sible that a protective effect could be attributable to bacterial poly-
saccharide antigens used in conjugate Hib vaccines. Most other
pediatric vaccines including measles, mumps, rubella, polio, diph-
theria, pertussis and tetanus consist of protein rather than poly-
saccharide antigens. Other bacterial polysaccharide vaccines such
as pneumococcus or meningococcus vaccines are seldom adminis-
tered to infants or young children.
In summary, our results based on a nation-wide vaccine trial
suggest a protective effect of Hib conjugate vaccine against child-
hood leukaemia, when administered at an early age. It remains
unclear, however, if the possible protective effect is due to Hib
vaccination per se or avoidance of infection.
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